COCP Cocrystal Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COCP

Price (delayed)

$1.13

Market cap

$21.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.76

Enterprise value

$20.75M

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 49
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 6

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. ...

Highlights
The debt has contracted by 19% YoY and by 6% from the previous quarter
Cocrystal Pharma's EPS has increased by 39% YoY but it has decreased by 4.1% from the previous quarter
Cocrystal Pharma's net income has increased by 21% YoY but it has decreased by 13% from the previous quarter
The company's equity has shrunk by 80% YoY and by 75% QoQ
The company's quick ratio has shrunk by 67% YoY and by 59% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cocrystalpharma.com
Peers: MRK USNA NATR JNJ

Key stats

What are the main financial stats of COCP

COCP stock price

How has the Cocrystal Pharma stock price performed over time
Intraday
-2.59%
1 week
-0.88%
1 month
20.21%
1 year
-22.62%
YTD
15.42%
QTD
7.62%

Financial performance

How have Cocrystal Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.44M
Net income
-$9.94M
Gross margin
N/A
Net margin
N/A
Cocrystal Pharma's net income has increased by 21% YoY but it has decreased by 13% from the previous quarter
The operating income has grown by 18% YoY but it has contracted by 13% from the previous quarter

Price vs fundamentals

How does COCP's price correlate with its fundamentals

Growth

What is Cocrystal Pharma's growth rate over time

Valuation

What is Cocrystal Pharma stock price valuation
P/E
N/A
P/B
14.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Cocrystal Pharma's EPS has increased by 39% YoY but it has decreased by 4.1% from the previous quarter
The stock's P/B is 189% above its last 4 quarters average of 5.3
The company's equity has shrunk by 80% YoY and by 75% QoQ

Efficiency

How efficient is Cocrystal Pharma business performance
COCP's return on invested capital is down by 50% since the previous quarter and by 39% year-on-year
Cocrystal Pharma's ROE has decreased by 44% YoY and by 38% from the previous quarter
The ROA has contracted by 26% from the previous quarter and by 20% YoY

Dividends

What is COCP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COCP.

Financial health

How did Cocrystal Pharma financials performed over time
The total assets is 29% more than the total liabilities
The company's quick ratio has shrunk by 67% YoY and by 59% QoQ
The company's current ratio has shrunk by 66% YoY and by 53% QoQ
The debt is 28% more than the equity
The company's equity has shrunk by 80% YoY and by 75% QoQ
The debt has contracted by 19% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.